3月19日 - ** 基因治疗开发商Regenxbio的RGNX.O股价上涨4.5%，至8.15美元
** Co公司公布了其实验性基因疗法RGX-202治疗杜氏肌肉萎缩症（Duchenne muscular dystrophy）的早期中期数据(DMD)
** DMD会导致骨骼和心脏肌肉无力，并随着时间的推移迅速恶化
** 两名新增患者（其中一名为3岁儿童）的临时数据证实了4岁以上患者的安全性和有效性——RGNX
** Co表示没有发生严重的不良事件
** Co计划在2025年上半年分享进一步的早期功能数据
** 包括疗程收益在内，RGNX在过去12个月中下跌了63
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.